Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nuclear Export Inhibition for Radiosensitization: A Proof-of-Concept Phase 1 Clinical Trial of Selinexor (KPT-330) Combined With Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Lawrence YR, Shacham-Shmueli E, Yarom N, Khaikin M, Venturero M, Apter S, Inbar Y, Symon Z, Aderka D, Halpern N, Berger R, Boursi B, Jacobson G, Raskin S, Ackerstein A, Margalit O, Appel S, Schvimer M, Crochiere M, Yang F, Landesman Y, Rashal T, Shacham S, Golan T. Lawrence YR, et al. Among authors: ackerstein a. Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):250-255. doi: 10.1016/j.ijrobp.2022.05.026. Epub 2022 Jun 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 35667526 Clinical Trial. No abstract available.
A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.
Nagler A, Berger R, Ackerstein A, Czyz JA, Diez-Martin JL, Naparstek E, Or R, Gan S, Shimoni A, Slavin S. Nagler A, et al. Among authors: ackerstein a. J Immunother. 2010 Apr;33(3):326-33. doi: 10.1097/CJI.0b013e3181c810b6. J Immunother. 2010. PMID: 20445353 Clinical Trial.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Rodon J, et al. Among authors: ackerstein a. Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011205 Free PMC article. Clinical Trial.
Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.
Or R, Ackerstein A, Nagler A, Amar A, Naparstek E, Varadi G, Kapelushnik J, Samuel S, Pugatsch T, Brautbar C, Slavin S. Or R, et al. Among authors: ackerstein a. J Immunother. 1998 Nov;21(6):447-53. doi: 10.1097/00002371-199811000-00007. J Immunother. 1998. PMID: 9807740 Clinical Trial.
Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.
Slavin S, Ackerstein A, Or R, Shapira MY, Gesundheit B, Askenasy N, Morecki S. Slavin S, et al. Among authors: ackerstein a. Cancer Immunol Immunother. 2010 Oct;59(10):1511-9. doi: 10.1007/s00262-010-0878-1. Epub 2010 Jun 20. Cancer Immunol Immunother. 2010. PMID: 20563804 Free PMC article. Clinical Trial.
Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
Morecki S, Revel-Vilk S, Nabet C, Pick M, Ackerstein A, Nagler A, Naparstek E, Ben Shahar M, Slavin S. Morecki S, et al. Among authors: ackerstein a. Cancer Immunol Immunother. 1992;35(6):401-11. doi: 10.1007/BF01789019. Cancer Immunol Immunother. 1992. PMID: 1394343 Free PMC article. Clinical Trial.
69 results